Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by Versor Investments LP

Versor Investments LP lifted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 36.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,582 shares of the specialty pharmaceutical company’s stock after buying an additional 5,200 shares during the period. Versor Investments LP owned approximately 0.06% of Collegium Pharmaceutical worth $561,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. Foundry Partners LLC lifted its position in Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock worth $610,000 after buying an additional 509 shares in the last quarter. Caprock Group LLC lifted its position in Collegium Pharmaceutical by 6.7% during the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock worth $249,000 after buying an additional 543 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after buying an additional 642 shares during the last quarter.

Collegium Pharmaceutical Stock Up 2.2 %

Shares of NASDAQ:COLL opened at $29.05 on Friday. The company has a market capitalization of $936.86 million, a price-to-earnings ratio of 12.52 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 12-month low of $27.84 and a 12-month high of $42.29. The business has a 50-day moving average price of $30.82 and a 200 day moving average price of $33.47. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on COLL. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. Finally, Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.